Baxter Unveils Mission and Logo for Proposed Kidney Care Company Vantive

Baxter, a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.

The Vantive mission, “Extending Lives, Expanding Possibilities,” will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond. This mission will drive Vantive employees to passionately develop solutions that address the very human and often individual needs of clinicians and patients, always striving to shape a better healthcare experience.

The Vantive logo features a “V” motif divided into three parts, representing the innovative therapies, digital solutions, and advanced services the company delivers. The logo is depicted in plum, a color that combines the stability and trustworthiness of blue, Baxter’s primary brand color, with the energy and boldness of red.

“With the reveal of our mission and logo, we have reached another critical milestone in our journey to establish Vantive. From our legacy as a pioneer in kidney care to our position as a market leader in chronic and acute therapies, we maintain a unique vantage point to help fulfill the pivotal needs of today’s clinicians and patients,” said Chris Toth, executive vice president and group president of Kidney Care at Baxter, who will serve as chief executive officer of Vantive upon separation.

Vantive will carry forward Baxter’s nearly 70-year legacy as a pioneer and leader in kidney care and vital organ support therapies. The company will continue to serve as a trusted partner to providers and clinicians worldwide, focusing on improving outcomes for more than one million patients it serves annually in over 70 countries.

Baxter announced plans in 2023 to create a new Kidney Care company from its Renal Care and Acute Therapies businesses. The new Vantive branding will come into effect when the separation occurs, currently expected in the second half of 2024, either through a sale to a private equity investor or a spinoff into a publicly traded company.

Until the proposed separation is completed, the Kidney Care business will continue to operate as Baxter. Read more about the proposed Kidney Care separation here.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter